Literature DB >> 11318766

Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses.

K I Melkersson1, A L Hulting, A J Rane.   

Abstract

AIMS: The aim of this study was to investigate the prolactin (PRL) secretion and the growth hormone (GH)-insulin-like growth factor I (IGF-I) axis in relation to gender and side-effects and dose of antipsychotic drugs during long-term treatment.
METHODS: Forty-seven patients (21 men and 26 women), diagnosed with schizophrenia or related psychoses according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria and treated with different classical antipsychotics, were studied. Prolactin, GH and IGF-I were measured, as well as the serum concentration of the antipsychotics. In addition, body mass index (BMI) was calculated.
RESULTS: The median daily, as well as the median body weight, adjusted daily dose of antipsychotic drugs was twofold higher in male compared with female patients. Antipsychotic-induced hyperprolactinaemia was more frequent and occurred at a lower daily dose of antipsychotics in women. Irrespective of sex, more than half of the patients had elevated BMI. Two patients had a slight increment in IGF-I levels, whereas the GH concentration, as assessed on a single occasion, was normal in all patients.
CONCLUSIONS: Patients on long-term antipsychotic therapy, with doses adjusted according to therapeutic efficiency, exhibited hyperprolactinaemia and elevated BMI, but no obvious influence on the GH-IGF-I axis. Furthermore, it appeared that the males required twice the dose of antipsychotic compared with females.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11318766      PMCID: PMC2014456          DOI: 10.1046/j.1365-2125.2001.01352.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  31 in total

Review 1.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

2.  Gender differences in the course of schizophrenia.

Authors:  J M Goldstein
Journal:  Am J Psychiatry       Date:  1988-06       Impact factor: 18.112

Review 3.  Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication.

Authors:  K A Yonkers; J C Kando; J O Cole; S Blumenthal
Journal:  Am J Psychiatry       Date:  1992-05       Impact factor: 18.112

Review 4.  Psychotropic drug induced weight gain: mechanisms and management.

Authors:  J G Bernstein
Journal:  Clin Neuropharmacol       Date:  1988       Impact factor: 1.592

5.  Prolactin responses to neuroleptics in normal and schizophrenic subjects.

Authors:  P H Gruen; E J Sachar; G Langer; N Altman; M Leifer; A Frantz; F S Halpern
Journal:  Arch Gen Psychiatry       Date:  1978-01

6.  Some endocrine effects of phenothiazines: a preliminary report.

Authors:  P J Beumont; G W Harris; P J Carr; H G Friesen; T Kolakowska; P C MacKinnon; B M Mandelbrote; D Wiles
Journal:  J Psychosom Res       Date:  1972-08       Impact factor: 3.006

Review 7.  Weight gain associated with neuroleptic medication: a review.

Authors:  J M Stanton
Journal:  Schizophr Bull       Date:  1995       Impact factor: 9.306

Review 8.  Regulation of prolactin secretion by oestrogens: physiological and pathological significance.

Authors:  S Franks
Journal:  Clin Sci (Lond)       Date:  1983-11       Impact factor: 6.124

9.  Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients.

Authors:  N Yasui; G Tybring; K Otani; K Mihara; A Suzuki; J O Svensson; S Kaneko
Journal:  Pharmacogenetics       Date:  1997-10

Review 10.  Weight gain associated with psychotropic drugs.

Authors:  K T Brady
Journal:  South Med J       Date:  1989-05       Impact factor: 0.954

View more
  11 in total

Review 1.  Role of estrogen treatment in the management of schizophrenia.

Authors:  Jayashri Kulkarni; Emmy Gavrilidis; Roisin Worsley; Emily Hayes
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

Review 2.  Sex steroids and schizophrenia.

Authors:  Julie A Markham
Journal:  Rev Endocr Metab Disord       Date:  2012-09       Impact factor: 6.514

3.  Electrophysiological Neuroimaging using sLORETA Comparing 22 Age Matched Male and Female Schizophrenia Patients.

Authors:  Andy R Eugene; Jolanta Masiak; Jacek Kapica; Marek Masiak; Richard M Weinshilboum
Journal:  Hosp Chron       Date:  2015

4.  Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants.

Authors:  Hsien-Yuan Lane; Yue-Cune Chang; Chih-Chiang Chiu; Sue-Hong Lee; Cher-Yeang Lin; Wen-Ho Chang
Journal:  Psychopharmacology (Berl)       Date:  2003-12-09       Impact factor: 4.530

5.  Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.

Authors:  Rodrigo A Bressan; Kjell Erlandsson; Edgar P Spencer; Peter J Ell; Lyn S Pilowsky
Journal:  Psychopharmacology (Berl)       Date:  2004-09       Impact factor: 4.530

6.  Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study.

Authors:  Zeynep Kotan; Berrin Ertepe; Cengiz Akkaya; Emre Sarandol; Güven Ozkaya; Selçuk Kirli
Journal:  Ther Adv Psychopharmacol       Date:  2011-12

7.  Prolactin levels in olanzapine treatment correlate with positive symptoms of schizophrenia: results from an open-label, flexible-dose study.

Authors:  Yi-Lung Chen; Ting-Sheng Cheng; For-Wey Lung
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

8.  Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study.

Authors:  S Pouwels; T P van Staa; A C G Egberts; H G M Leufkens; C Cooper; F de Vries
Journal:  Osteoporos Int       Date:  2009-01-21       Impact factor: 4.507

9.  Comparison of Plasma Neurosteroid and Prolactin Levels in Patients with Schizophrenia and Healthy Individuals.

Authors:  Forough Riahi; Maryam Izadi-Mazidi; Ali Ghaffari; Elham Yousefi; Shahram Khademvatan
Journal:  Scientifica (Cairo)       Date:  2016-05-10

Review 10.  Significantly Higher Peripheral Insulin-Like Growth Factor-1 Levels in Patients With Major Depressive Disorder or Bipolar Disorder Than in Healthy Controls: A Meta-Analysis and Review Under Guideline of PRISMA.

Authors:  Kun-Yu Tu; Ming-Kung Wu; Yen-Wen Chen; Pao-Yen Lin; Hung-Yu Wang; Ching-Kuan Wu; Ping-Tao Tseng
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.